DENVER–(BUSINESS WIRE)–EvoEndo®, Inc. (“EvoEndo”), a medical device company which developed a single use system that allows for unsedated Transnasal Endoscopy (TNE), has announced the completion of an $8.4 million Series A financing round led by founding investor TLP Investment Partners LLC (TLP) and including the Sunshine Charitable Foundation and the Jill and Paul Meister family. Proceeds from the financing will be used to support the initial commercial launch of the EvoEndo® Single-Use Endoscopy System by hiring additional personnel and growing inventory capacity. The company will also deploy the funding to conduct clinical and post-market surveillance studies.
Trending
- Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn’s disease: 5-year follow-up of the PROFILE trial (The Lancet Gastroenterology & Hepatology)
- Low AST and ALT Levels Are Associated with Higher Likelihood of Early-Onset Colorectal Cancer in Adults Under 45 (Epic Research)
- Helicobacter pylori exposure linked to one in five cases of bowel cancer (News Medical)
- FDA Clears CU Anschutz Clinical Trial Using Engineered Immune Cells to Fight Colorectal Cancer (PR Newswire)
- A robot pill the size of a large vitamin swims through a stomach on 6 water jets while a doctor steers it with a game controller, and after $21 million it still cannot be used on a patient (The Pulse)
- GLP-1 users can have ‘terrific results’ with bariatric surgery to lose additional weight (Healio)
- GI faces another round of Medicare cuts under proposed 2027 rules (GI & Hepatology News)
- Fecal Occult Blood Screening Outcomes Adjusted for Contamination Bias and Nonadherence (JAMA Network)
